Angiopoietin-2 (Ang-2) has been identified as a potential biomarker for ovarian cancer spread to lymph nodes and is associated with patient prognosis, potentially serving as a marker to identify patients who would benefit from bevacizumab treatment (106). This evidence concerns the gene ANGPT2 and ovarian carcinoma.